The signaling signature of the neurotensin type 1 receptor with endogenous ligands
\'Elie Besserer-Offroy, Rebecca L Brouillette, Sandrine Lavenus,, Ulrike Froehlich, Andrea Brumwell, Alexandre Murza, Jean-Michel Longpr\'e,, \'Eric Marsault, Michel Grandbois, Philippe Sarret, and Richard Leduc

TL;DR
This study characterizes the complex signaling pathways activated by the human neurotensin 1 receptor (hNTS1) using biosensors, revealing ligand-specific pathway engagement and potential for biased ligand development.
Contribution
It provides a detailed analysis of hNTS1 signaling pathways and introduces a comprehensive method to evaluate ligand bias and receptor activation mechanisms.
Findings
Neurotensin, NT(8-13), and neuromedin N activate multiple G protein pathways.
All ligands stimulate inositol phosphate production and cAMP modulation.
Full ERK1/2 activation involves both Gi/o and Gq pathways.
Abstract
The human neurotensin 1 receptor (hNTS1) is a G protein-coupled receptor involved in many physiological functions, including analgesia, hypothermia, and hypotension. To gain a better understanding of which signaling pathways or combination of pathways are linked to NTS1 activation and function, we investigated the ability of activated hNTS1, which was stably expressed by CHO-K1 cells, to directly engage G proteins, activate second messenger cascades and recruit \b{eta}-arrestins. Using BRET-based biosensors, we found that neurotensin (NT), NT(8-13) and neuromedin N (NN) activated the G{\alpha}q-, G{\alpha}i1-, G{\alpha}oA-, and G{\alpha}13-protein signaling pathways as well as the recruitment of \b{eta}-arrestins 1 and 2. Using pharmacological inhibitors, we further demonstrated that all three ligands stimulated the production of inositol phosphate and modulation of cAMP accumulation…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
